反应引导的新辅助戈沙妥珠单抗治疗局限性三阴性乳腺癌:NeoSTAR试验结果
NeoSTAR是一项研究者发起的临床试验,评估新辅助戈沙妥珠单抗(SG)治疗早期三阴性乳腺癌的疗效。50例患者接受4周期SG,单药病理完全缓解(pCR)率为30%(n=15,95%CI 18%~45%),总缓解率(ORR)为64%(n=32/50,95%CI 77%~98%)。中位随访18.9个月,2年无事件生存(EFS)率为95%,达到pCR者2年EFS率为100%。
要点
- 新辅助SG单药治疗早期三阴性乳腺癌的pCR率为30%(95%CI 18%~45%)。
- Ki-67和肿瘤浸润淋巴细胞(TILs)较高可预测SG的pCR(P=0.007和P=0.002)。
- 常见不良事件为恶心(82%)、疲乏(76%)、脱发(76%)、中性粒细胞减少(44%)和皮疹(48%)。
核心结论
- 在首个针对局限性三阴性乳腺癌的新辅助抗体药物偶联物(ADC)试验中,SG显示出单药疗效以及反应引导的升级/降级治疗的可行性。
- 需要进一步研究SG的最佳持续时间以及包括免疫治疗在内的新辅助联合策略。
研究设计与样本
- 研究者发起的临床试验(NCT04230109),早期三阴性乳腺癌患者接受4周期新辅助SG治疗。
- 主要目标为评估乳腺和淋巴结的病理完全缓解率(ypT0/isN0)。
- 次要目标包括总缓解率、安全性、无事件生存和预测生物标志物。
- 采用反应引导方法,后续全身治疗决策由治疗医生自行决定。
- 2020年7月至2021年8月共入组50例参与者(中位年龄48.5岁;临床I期13例,II期26例,III期11例)。
主要发现
- 49例(98%)完成了4周期SG治疗。
- 单用SG的pCR率为30%(n=15,95%CI 18%~45%)。
- 单用SG后按RECIST V1.1评估的ORR为64%(n=32/50,95%CI 77%~98%)。
- 较高的Ki-67和肿瘤浸润淋巴细胞可预测SG的pCR(Ki-67 P=0.007,TILs P=0.002),而基线TROP2表达不能预测(P=0.440)。
- 中位随访时间18.9个月(95%CI 16.3~21.9个月),所有参与者2年EFS率为95%;达到pCR者(n=15)2年EFS率为100%。
关键数值与推荐
- 单用SG的pCR率为30%(n=15,95%CI 18%~45%)。
- 单用SG后ORR为64%(n=32/50,95%CI 77%~98%)。
- Ki-67预测pCR的P=0.007,TILs预测pCR的P=0.002,基线TROP2表达预测pCR的P=0.440。
- 常见不良事件:恶心82%、疲乏76%、脱发76%、中性粒细胞减少44%、皮疹48%。
- 所有参与者2年EFS率为95%,达到pCR者2年EFS率为100%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sacituzumab govitecan (SG), a novel antibody-drug conjugate (ADC) targeting TROP2, is approved for pre-treated metastatic triple-negative breast cancer (mTNBC). We conducted an investigator-initiated clinical trial evaluating neoadjuvant (NA) SG (NCT04230109), and report primary results. PATIENTS AND METHODS: Participants with early-stage TNBC received NA SG for four cycles. The primary objective was to assess pathological complete response (pCR) rate in breast and lymph nodes (ypT0/isN0) to SG. Secondary objectives included overall response rate (ORR), safety, event-free survival (EFS), and predictive biomarkers. A response-guided approach was utilized, and subsequent systemic therapy decisions were at the discretion of the treating physician. RESULTS: From July 2020 to August 2021, 50 participants were enrolled (median age = 48.5 years; 13 clinical stage I disease, 26 stage II, 11 stage III). Forty-nine (98%) completed four cycles of SG. Overall, the pCR rate with SG alone was 30% [n = 15, 95% confidence interval (CI) 18% to 45%]. The ORR per RECIST V1.1 after SG alone was 64% (n = 32/50, 95% CI 77% to 98%). Higher Ki-67 and tumor-infiltrating lymphocytes (TILs) were predictive of pCR to SG (P = 0.007 for Ki-67 and 0.002 for TILs), while baseline TROP2 expression was not (P = 0.440). Common adverse events were nausea (82%), fatigue (76%), alopecia (76%), neutropenia (44%), and rash (48%). With a median follow-up time of 18.9 months (95% CI 16.3-21.9 months), the 2-year EFS for all participants was 95%. Among participants with a pCR with SG (n = 15), the 2-year EFS was 100%. CONCLUSIONS: In the first NA trial with an ADC in localized TNBC, SG demonstrated single-agent efficacy and feasibility of response-guided escalation/de-escalation. Further research on optimal duration of SG as well as NA combination strategies, including immunotherapy, are needed.
引用
- Spring LM, Tolaney SM, Fell G, et al. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2023. PMID: 38092228. doi:10.1016/j.annonc.2023.11.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。